<DOC>
	<DOC>NCT01045083</DOC>
	<brief_summary>This is an exploratory study to evaluate the usefulness of fMRI as a biomarker to characterize the response to three centrally active drugs and placebo.</brief_summary>
	<brief_title>A Study of the Ability of Functional Magnetic Resonance Imaging (fMRI) to Detect and Characterize the Effects of Two Marketed Centrally Active Drugs, Placebo, and RO4917523 in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Adult patients, 18 to 45 years of age In good general health Weight of &amp;#x2265;120 lbs (55 kg) and a body mass index (BMI) between 18 to 30kg/mÂ² Males and females with reproductive potential: willing to use a reliable method of contraception Evidence of clinically significant disease Medical or surgical condition that could alter the absorption, metabolism, or elimination of drugs Family history of sudden death or ventricular arrhythmia History of any psychiatric disorder and/or marked anxiety History of glaucoma History (including family) of motor tic or diagnosis of Tourette's syndrome Active suicide ideation Contraindication to MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>